InfuSystem Holdings Inc
AMEX:INFU
InfuSystem Holdings Inc
InfuSystem Holdings, Inc. engages in the provision of healthcare services. The company is headquartered in Rochester Hills, Michigan and currently employs 420 full-time employees. The company went IPO on 2006-06-15. The Company’s segments include Integrated Therapy Services (ITS) and Durable Medical Equipment Services (DME Services). The Company’s core service within its ITS segment is its Oncology Business. The ITS segment supplies electronic ambulatory infusion pumps and associated disposable supply kits to private oncology clinics, infusion clinics and hospital outpatient oncology clinics to be utilized in the treatment of a variety of cancers, including colorectal cancer and other disease states. Its DME Services segments core service is to sell or rent new and pre-owned pole-mounted and ambulatory infusion pumps and other Durable Medical Equipment; sell treatment-related consumables; and provide biomedical recertification, maintenance and repair services for oncology practices as well as other healthcare site settings.
InfuSystem Holdings, Inc. engages in the provision of healthcare services. The company is headquartered in Rochester Hills, Michigan and currently employs 420 full-time employees. The company went IPO on 2006-06-15. The Company’s segments include Integrated Therapy Services (ITS) and Durable Medical Equipment Services (DME Services). The Company’s core service within its ITS segment is its Oncology Business. The ITS segment supplies electronic ambulatory infusion pumps and associated disposable supply kits to private oncology clinics, infusion clinics and hospital outpatient oncology clinics to be utilized in the treatment of a variety of cancers, including colorectal cancer and other disease states. Its DME Services segments core service is to sell or rent new and pre-owned pole-mounted and ambulatory infusion pumps and other Durable Medical Equipment; sell treatment-related consumables; and provide biomedical recertification, maintenance and repair services for oncology practices as well as other healthcare site settings.
Revenue Growth: InfuSystem reported Q4 net revenue of $36.2 million, up 7% from the prior year, with both Patient Services and Device Solutions contributing.
Margin Improvement: Adjusted EBITDA for Q4 rose 17% to $8.8 million and full-year adjusted EBITDA grew 24% to $31.5 million, with margins now in the low to mid-20% range.
Strategic Restructuring: The company restructured a major biomedical services contract, reducing annual revenue by $7.1 million but expecting a larger reduction in expenses, benefiting margins.
2026 Guidance: Management expects 2026 annual revenue growth of 6% to 8% and sustained adjusted EBITDA margins in the mid- to low-20% range.
Cash Flow & Liquidity: Operating cash flow increased to $24.4 million for the full year, net debt declined by 30%, and liquidity stood at $58 million end of Q4.
Technology Upgrades: Major IT and revenue cycle system upgrades are nearly complete, expected to reduce annual costs by $2 million and improve efficiency starting later in 2026.
Shareholder Returns: The company repurchased $9.9 million in shares during 2025, retiring 1.3 million shares for the year.
